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Abstract
The aim of this study was to evaluate germline variant frequencies of pheochromocytoma and paraganglioma targeted susceptibility genes with 
next-generation sequencing method. Germline DNA from 75 cases were evaluated with targeted next-generation sequencing on an Illumina 
NextSeq550 instrument. KIF1B, RET, SDHB, SDHD, TMEM127, and VHL genes were included in the study, and Sanger sequencing was used 
for verifying the variants. The pathogenic/likely pathogenic variants were in the VHL, RET, SDHB, and SDHD genes, and the diagnosis rate was 
24% in this study. Three different novel pathogenic variants were determined in five cases. This is the first study from Turkey, evaluating germline 
susceptibility genes of pheochromocytoma and paraganglioma with a detection rate of 24% and three novel variants. All patients with pheo-
chromocytoma and paraganglioma need clinical genetic testing with expanded targeted gene panels for higher diagnosis rates.
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Paraganglioma and pheochromocytoma are defined as neu-
rogenic tumors arising from paraganglial cells found in neu-
roendocrine tissues (1). Paraganglionic tissues, on the other 
hand, are specialized cell groups and are generally found 
scattered throughout the body. These cells are mostly located 
in the adrenal medulla, aorta, vascular wall, heart, prostate, 
and ovaries (2). They are groups of cells in close proximity 
to the sympathetic and parasympathetic nervous system. 
Tumors originating from chromaffin cell groups are called 
pheochromocytomas. (3). Paragangliomas do not generally 
contain epinephrine and are not stained with chromium 
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salts. Therefore, these tumors are considered chromaffin neg-
ative. These paraganglial cell groups are found in the carotid, 
jugular glomus, aorticopulmonary glomus, vagus, and ciliary 
glomus where chemoreceptors are found in the body (1).
Von Hippel–Lindau (VHL) Syndrome is a hereditary can-
cer syndrome involving more than one system, character-
ized by benign or malignant tumors and cystic lesions (4). 
Hemangioblastomas, renal cysts and kidney cancer, pheo-
chromocytoma, pancreatic cysts and neuroendocrine tumors, 
endolymphatic sac tumors, and epididymal and ligamentum 
latum cysts may be seen in the brain, spinal cord, and ret-
ina  (5). Retinal hemangioblastomas are usually the first 
sign of the disease and cause vision loss. Up to 70% of the 
affected individuals can be diagnosed with retinal hemangio-
blastomas detected around the age of 25 (6, 7).
Pheochromocytoma associated with a pathogenic variant 
occurs at a younger age than pheochromocytoma cases with-
out any mutation (8). Although there is no clear age limit, 
having been diagnosed younger than 30–45 may indicate the 
presence of a mutation. SDHA, SDHAF2, SDHB, SDHC, 
SDHD, MAX, and TMEM127 genes are offered to be ana-
lyzed for the diagnosis of paraganglioma/pheochromocy-
toma (PGL/PCC) syndromes (9). For differential diagnosis, 
NF1, VHL, RET, and EPAS1 genes should be analyzed (10). 
In this study, a custom panel of KIF1B, RET, SDHB, SDHD, 
TMEM127, and VHL genes were analyzed with a targeted 
gene panel using next-generation sequencing method for 
rapid and cost-effective diagnosis and differential diagnosis 
in patients with PGL/PCC. Only these six genes could be 
analyzed, as this study was planned retrospectively and this 
custom panel was used between the years 2013 and 2020 in 
our department; this custom panel was designed firstly in 
2013 with only six genes. To our knowledge, this is the first 
study presenting germline pathogenic/likely pathogenic vari-




Seventy-five cases with a pre-diagnosis of PGL/PCC were 
examined in the Endocrinology Clinic and referred to the 
Medical Genetics clinic for molecular testing from August 
2013 through November 2020. Cases were included for hav-
ing high levels of blood or urinary catecholamines, meta-
nephrines, methoxytyramine, or chromogranin A, and/or a 
suspicion of PGL/PCC on imaging tests, and/or personal 
or family history of PGL/PCC in our study. Pediatric cases 
and/or adult cases who have not had any imaging tests due 
to pregnancy, breastfeeding, claustrophobia, medical condi-
tions, serious illness, and acute or chronic renal insufficiency 
were excluded from this study.
The cases had no relation except cases 4 and 5 who are 
brothers (Table 1).
The written informed consent forms were obtained from 
the patients or from their legal guardians. This study is 
approved by the Ethical Committee of our university with 
the number 2021/46 and performed in consonance with the 
principles of the Declaration of Helsinki.
Molecular analysis
Genomic DNA was isolated from peripheral blood samples 
with ethylenediaminetetraacetic acid tetrasodium salt dihy-
drate (EDTA) of the patients by using EZ1 DNA Investi-
gator Kit (Qiagen, Hilden, Germany). Primary quality 
control of the isolated DNA samples was performed using 
NanoDrop (Thermo Fisher Scientific, Waltham, MA), and 
samples having A260/280 values between 1.8 and 2.0 were 
included in the study.
QIAseq Targeted DNA Panel (Qiagen, Hilden, Germany) 
was performed to analyze six genes (KIF1B, RET, SDHB, 
SDHD, TMEM127, and VHL). Libraries were prepared 
according to the manufacturer’s instructions. Quality con-
trol of the prepared libraries was applied with Qubit dsDNA 
BR Assay system (Invitrogen, Carlsbad, CA). Fastq files 
were performed on Illumina NextSeq550 (Illumina Inc., San 
Diego, CA, ABD). Libraries covering the target genes were 
prepared according to the QIAseq Targeted DNA Panel 
protocol (Qiagen, Hilden, Germany). Following the target 
enrichment process, libraries were sequenced on the Illumina 
NextSeq550 (Illumina Inc., San Diego, CA, ABD). QCI 
analysis (Qiagen, Hilden, Germany) was used for Quality 
control and ordering Variant Call Format file. Variant anal-
ysis was performed with Ingenuity software (Qiagen, Hilden, 
Germany).
For verifying the variants and segregation analysis, prim-
ers were designed for all needed regions, and Sanger sequenc-
ing was performed using an ABI 3130 (Applied Biosystems, 
USA) capillary electrophoresis system.
Variant classification
ACMG-2015 (American College of Medical Genetics) (11) 
guidelines were followed for the classification of all the vari-
ants, and recommendations of the Human Genome Varia-
tion Society (12) were followed to describe the novel variants. 
ClinVar (13), HGMD-Professionel 2020 database, and litera-
ture information were considered for collecting the informa-
tion about known variants.
Results
Six different germline genes (KIF1B, RET, SDHB, SDHD, 
TMEM127, and VHL) were analyzed in 75 cases with a 
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pre-diagnosis of PGL/PCC. These genes were covered by 
241 amplicons with Custom QIAseq Paraganglioma Panel 
(CDHS-17364Z-241). Two hundred and thirty eight of 241 
amplicons (99%) yielded sequence reads, with a mean depth 
of 950 × per amplicon and sample.
The cases had a mean age of 40.4 (38 female cases with a 
mean age of 46.5; 37 male cases with a mean age of 34.1). 
Five of the patients (27.7%) had an affected family member.
Eighteen cases (24%) had pathogenic/likely pathogenic vari-
ants in our study. Six cases had pathogenic/likely pathogenic 
variants in VHL gene-four different variants. Five cases had 
five different pathogenic/likely pathogenic variants in RET 
gene. Four cases had three different pathogenic/likely patho-
genic variants (two novel variants) in SDHB gene. Three cases 
had two different pathogenic/likely pathogenic variants and 
one novel variant in SDHD gene. We detected three different 
novel pathogenic/likely pathogenic variants in this study.
Discussion
In the current study, we designed a targeted NGS assay 
for susceptibility genes to analyze the pheochromocytoma 
and/or paraganglioma. SDHB, SDHD, RET, and VHL 
genes showed pathogenic variants in our study. Five of 18 
cases (27.7%) were diagnosed with a novel pathogenic/likely 
pathogenic variant. Prevalence of germline mutations is an 
important consideration for offering molecular diagnostics.
In this study, six cases was diagnosed with VHL patho-
genic variants and the younger patient with VHL patho-
genic/likely pathogenic variant was 27 years old (Table 1, 
Case 3). He was diagnosed with metastatic bilateral surrenal 
adenomas. A study analyzing 86 unselected PGL/PCC tumor 
samples reported that two pathogenic variants were detected 
in VHL gene (14). VHL gene was also reported in 19.1% of 
the cases as the reason for bilateral pheochromocytoma (15). 
Fifty percent of our VHL cases had bilateral pheochromo-
cytoma, one case had also eye involvement and pancreatic 
cysts, and one case had liver cysts (Table 1).
In the current study, five cases had different pathogenic RET 
variants with different clinical presentations as pheochromo-
cytoma, medullary thyroid cancer, and thyroid nodules. The 
ages of these cases were between 28 and 62 years. Medullary 
thyroid cancer is a rare tumor originating from the parafollic-
ular C cells of the thyroid, and it is characterized by RET pro-
to-oncogene mutation in almost all hereditary cases and more 
than 40% of sporadic cases (16). In addition to clinical findings 
in medullary thyroid cancer evaluation, RET proto-oncogene 
mutation screening is highly recommended to determine gen-
otype-phenotype risks and to distinguish between sporadic 
and familial cases in terms of maintenance of the disease. RET 
polymorphic alleles were reported as an additive effect on the 
estimated risk of age-related pheochromocytoma penetrance in 
MEN2 patients (17). Pheochromocytoma in MEN2 patients is 
usually reported as bilateral and rarely to be metastatic (18). It 
was reported that analysis of patients with RET 634 mutations 
with and without pheochromocytoma showed that pheochro-
mocytoma was not associated with a more advanced stage of 
medullary thyroid cancer at diagnosis or a shorter survival (18). 
We detected codon 634 mutations in two cases (40%) of five 
RET-mutated cases—C634Y-mutated case had medullary thy-
roid cancer, and C634R-mutated case had pheochromocytoma. 
Similarly with the literature, our cases had mostly codon 634 
mutations. As a limitation of this single-center study, the cur-
rent cohort was limited. Codon 634 mutations were reported 
as the most frequent RET mutations in Brazil (19). C634Y 
(63.4%), C634R (28.2%), C634W (3.8%), C634G (3.1%), 
C634S (1.1%), and C634F (0.4%) mutations were reported in 
the same study (19). Codon 634 mutations were considered to 
be associated with an aggressive clinical course (20).
A 24-year-old female in the current study was diagnosed 
with right surrenal adenoma with a novel pathogenic variant 
NM_003002.4:c.326A>G on SDHD gene (Table 1, Case 18). 
The same variant was detected in another 82-year-old female 
who has no relation with the abovementioned 24-year-old 
female (Table 1, Case 17). Another SDHD pathogenic vari-
ant was detected in a 30-year-old male who had right surre-
nal adenoma (Table 1 case 16). SDHD and SDHB genes were 
reported as the most important causative genes of heredi-
tary PGL/PCC in Asia when patients are tested with multi-
gene NGS panel (21). In a case from Turkey, an 81-year-old 
female was reported with multinodular goiter and essential 
hypertension had NM_003002.3:c.325C>T (Gln109Term) 
pathogenic variant in SDHD gene (22).
Two different novel pathogenic SDHB variants were 
detected in four cases in our study. All these four cases 
involved young patients who were not related with each 
other. Distinct differences were reported in the clinical and 
histopathological characteristics between genetic variants in 
SDHB (23). Our two nonrelated cases had the same novel 
pathogenic variant (NM_003000.3:c.262A>C) in SDHB 
gene with different clinical presentations (Table 1, cases 14 
and 15) (Figure 1). 58 tumor samples (55 PGL, including 
45 head and neck PGL, 2 PCC, 1 GIST) were analysed in 
a study, and pathogenic variants in 50 patients (22 (13%) 
SDHB, 1 (3.2%) SDHC and 27 (57%) SDHD) were detected 
(24). We analyzed germline variants in this study, and the fre-
quencies of the pathogenic variants were 5.3% and 4% for 
SDHB and SDHD genes, respectively.
In our study, SDHB carriers had no metastasis; only one 
case had hypertrophic cardiomyopathy, additively (Table 1, 
Case 15). Metastatic disease occurs in 2–23% of all paragan-
glioma cases and is a major cause of mortality (25). SDHB 
carriers were reported to have the highest risk for metasta-
sis (26). Genetic counseling was given to these SDHB cases 
and their relatives for future risks, and they have been con-
sidered for clinical follow-up.
Pathogenic variants in pheochromocytoma and paraganglioma
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panels are needed for determining the prevalence and geno-
type-phenotype correlations for PGL/PCC patients.
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